148 related articles for article (PubMed ID: 25925043)
1. [Not Available].
García Layana A; Donate López J
Arch Soc Esp Oftalmol; 2015 Mar; 90 Suppl 1():1-2. PubMed ID: 25925043
[No Abstract] [Full Text] [Related]
2. [Management of aflibercept in routine clinical practice].
Cabrera López F
Arch Soc Esp Oftalmol; 2015 Mar; 90 Suppl 1():29-34. PubMed ID: 25925049
[TBL] [Abstract][Full Text] [Related]
3. [Role of VEGF in diseases of the retina].
Barquet LA
Arch Soc Esp Oftalmol; 2015 Mar; 90 Suppl 1():3-5. PubMed ID: 25925044
[TBL] [Abstract][Full Text] [Related]
4. [New perspectives in the approach to diabetic macular edema. Aflibercept therapy].
Ruiz-Moreno JM
Arch Soc Esp Oftalmol; 2015 Mar; 90 Suppl 1():24-8. PubMed ID: 25925048
[TBL] [Abstract][Full Text] [Related]
5. [New perspectives in the approach to age-related macular degeneration].
Gallego-Pinazo R; Zapata MA
Arch Soc Esp Oftalmol; 2015 Mar; 90 Suppl 1():11-4. PubMed ID: 25925046
[TBL] [Abstract][Full Text] [Related]
6. Results of a Randomized Clinical Trial of Aflibercept vs Panretinal Photocoagulation for Proliferative Diabetic Retinopathy: Is It Time to Retire Your Laser?
Glassman AR
JAMA Ophthalmol; 2017 Jul; 135(7):685-686. PubMed ID: 28570733
[No Abstract] [Full Text] [Related]
7. Cost Evaluation of Laser versus Intravitreal Aflibercept for Proliferative Diabetic Retinopathy.
Yannuzzi NA; Sridhar J; Chang JS; Lin J; Kuriyan AE; Smiddy WE
Ophthalmology; 2018 Jul; 125(7):1121-1122. PubMed ID: 29571831
[No Abstract] [Full Text] [Related]
8. [Switching to eylea in macular edema due to retinal vascular diseases].
Pascual-Camps I; Hernández-Martínez P; Ruiz J; Dolz-Marco R; Cuellar MJ; Gallego-Pinazo R
Arch Soc Esp Oftalmol; 2015 Jan; 90(1):48. PubMed ID: 25200895
[No Abstract] [Full Text] [Related]
9. Tyrosine kinase blocking collagen IV-derived peptide suppresses ocular neovascularization and vascular leakage.
Silva RLE; Kanan Y; Mirando AC; Kim J; Shmueli RB; Lorenc VE; Fortmann SD; Sciamanna J; Pandey NB; Green JJ; Popel AS; Campochiaro PA
Sci Transl Med; 2017 Jan; 9(373):. PubMed ID: 28100839
[TBL] [Abstract][Full Text] [Related]
10. Therapies for neovascular age-related macular degeneration: current approaches and pharmacologic agents in development.
Hanout M; Ferraz D; Ansari M; Maqsood N; Kherani S; Sepah YJ; Rajagopalan N; Ibrahim M; Do DV; Nguyen QD
Biomed Res Int; 2013; 2013():830837. PubMed ID: 24319688
[TBL] [Abstract][Full Text] [Related]
11. Short-term effects of a single intravitreal bevacizumab injection on retinal vessel calibre.
Tatlipinar S; Dinç UA; Yenerel NM; Görgün E
Clin Exp Optom; 2012 Jan; 95(1):94-8. PubMed ID: 21954975
[TBL] [Abstract][Full Text] [Related]
12. [New drug VEGF Trap-Eye--Eylea--and its use in the treatment of age-related macular degeneration, central retinal vein occlusion, diabetic macular edema, and choroidal neovascularization secondary to pathologic myopia].
Rejdak R; Szkaradek M; Taslaq W; Kałuzny JJ; Grieb P; Jünemann AG
Klin Oczna; 2012; 114(4):308-10. PubMed ID: 23461161
[TBL] [Abstract][Full Text] [Related]
13. [Aflibercept. An approach to pharmacology].
Azanza Perea JR; Sádaba B
Arch Soc Esp Oftalmol; 2015 Mar; 90 Suppl 1():6-10. PubMed ID: 25925045
[TBL] [Abstract][Full Text] [Related]
14. Three-month outcomes of ziv-aflibercept in the treatment of diabetic macular oedema.
Ashraf M; Souka AA; El Kayal H; El Manhaly M; Abdallah MH
Acta Ophthalmol; 2016 Nov; 94(7):e669. PubMed ID: 27227354
[No Abstract] [Full Text] [Related]
15. DRCR Protocol-T: Reconciling 1- and 2-Year Data for Managing Diabetic Macular Edema.
Wykoff CC; Hariprasad SM
Ophthalmic Surg Lasers Imaging Retina; 2016 Apr; 47(4):308-12. PubMed ID: 27065368
[No Abstract] [Full Text] [Related]
16. Quantification of Change in Pigment Epithelial Detachment Volume and Morphology After Transition to Intravitreal Aflibercept in Eyes With Recalcitrant Neovascular AMD: 18-Month Results.
Kanesa-Thasan A; Grewal DS; Gill MK; Lyon AT; Mirza RG
Ophthalmic Surg Lasers Imaging Retina; 2015 Jun; 46(6):638-41. PubMed ID: 26114844
[TBL] [Abstract][Full Text] [Related]
17. Comparing aflibercept, bevacizumab, and ranibizumab for DME: analysis of DRCR Protocol T.
Wykoff CC; Hariprasad SM
Ophthalmic Surg Lasers Imaging Retina; 2015 Mar; 46(3):302-5. PubMed ID: 25835307
[No Abstract] [Full Text] [Related]
18. Author reply: To PMID 25012934.
Brown DM; Korobelnik JF;
Ophthalmology; 2015 Jun; 122(6):e38-9. PubMed ID: 26008916
[No Abstract] [Full Text] [Related]
19. Re: Korobelnik et al.: Intravitreal aflibercept for diabetic macular edema (Ophthalmology 2014;121:2247-54).
Hashmonay R; Parikh S
Ophthalmology; 2015 Jun; 122(6):e37-8. PubMed ID: 26008915
[No Abstract] [Full Text] [Related]
20. [Research progress of anti-angiogenesis drug targets in diabetic retinopathy].
Wu W; Tang L
Zhonghua Yan Ke Za Zhi; 2014 Nov; 50(11):871-6. PubMed ID: 25582212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
